Protection by BCG Vaccine Against Tuberculosis: A Systematic Review of Randomized Controlled Trials
Top Cited Papers
Open Access
- 13 December 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 58 (4), 470-480
- https://doi.org/10.1093/cid/cit790
Abstract
Background. Randomized trials assessing BCG vaccine protection against tuberculosis have widely varying results, for reasons that are not well understood. Methods. We examined associations of trial setting and design with BCG efficacy against pulmonary and miliary or meningeal tuberculosis by conducting a systematic review, meta-analyses, and meta-regression. Results. We identified 18 trials reporting pulmonary tuberculosis and 6 reporting miliary or meningeal tuberculosis. Univariable meta-regression indicated efficacy against pulmonary tuberculosis varied according to 3 characteristics. Protection appeared greatest in children stringently tuberculin tested, to try to exclude prior infection with Mycobacterium tuberculosis or sensitization to environmental mycobacteria (rate ratio [RR], 0.26; 95% confidence interval [CI], .18–.37), or infants (RR, 0.41; 95% CI, .29–.58). Protection was weaker in children not stringently tested (RR, 0.59; 95% CI, .35–1.01) and older individuals stringently or not stringently tested (RR, 0.88; 95% CI, .59–1.31 and RR, 0.81; 95% CI, .55–1.22, respectively). Protection was higher in trials further from the equator where environmental mycobacteria are less and with lower risk of diagnostic detection bias. These associations were attenuated in a multivariable model, but each had an independent effect. There was no evidence that efficacy was associated with BCG strain. Protection against meningeal and miliary tuberculosis was also high in infants (RR, 0.1; 95% CI, .01–.77) and children stringently tuberculin tested (RR, 0.08; 95% CI, .03–.25). Conclusions. Absence of prior M. tuberculosis infection or sensitization with environmental mycobacteria is associated with higher efficacy of BCG against pulmonary tuberculosis and possibly against miliary and meningeal tuberculosis. Evaluations of new tuberculosis vaccines should account for the possibility that prior infection may mask or block their effects.Keywords
This publication has 25 references indexed in Scilit:
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Genome plasticity of BCG and impact on vaccine efficacyProceedings of the National Academy of Sciences of the United States of America, 2007
- Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectivenessThe Lancet, 2006
- Nontuberculous Mycobacteria: Clinical Importance and Relevance to Bacille Calmette-Guerin VaccinationClinical Infectious Diseases, 2004
- How should meta‐regression analyses be undertaken and interpreted?Statistics in Medicine, 2002
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986
- B.C.G. and Vole Bacillus Vaccines in the Prevention of Tuberculosis in Adolescents: First (Progress) Report to the Medical Research CouncilBMJ, 1956
- BCG vaccination of Indian infants in Saskatchewan: A study carried out with financial assistance from the National Research Council of CanadaTubercle, 1949
- Ten years' experience with BCG (experimental and clinical)The Journal of Pediatrics, 1945